Nabriva Therapeutics Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Nabriva Therapeutics stock.
View analyst ratings for Nabriva Therapeutics or view top-rated stocks.

Wall Street analysts have given Nabriva Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nabriva Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Nabriva Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,260,000 shares, an increase of 39.5% from the February 28th total of 1,620,000 shares. Based on an average daily trading volume, of 2,110,000 shares, the short-interest ratio is currently 1.1 days. Currently, 7.8% of the company's stock are sold short.
View Nabriva Therapeutics' Short Interest.

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Nabriva Therapeutics.

Nabriva Therapeutics plc (NASDAQ:NBRV) posted its quarterly earnings data on Thursday, March, 11th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.17. The biotechnology company had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.61 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 129.80% and a negative net margin of 1,682.55%.
View Nabriva Therapeutics' earnings history.

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NBRV stock has increased by 21.5% and is now trading at $1.47.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued 12 month price objectives for Nabriva Therapeutics' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Nabriva Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 308.2% from the stock's current price.
View analysts' price targets for Nabriva Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Nabriva Therapeutics include Keros Therapeutics (KROS), Cassava Sciences (SAVA), Zealand Pharma A/S (ZEAL), Theravance Biopharma (TBPH), Aclaris Therapeutics (ACRS), Antibe Therapeutics (ATBPD), Olema Pharmaceuticals (OLMA), Endo International (ENDP), Cara Therapeutics (CARA), Protagonist Therapeutics (PTGX), Avid Bioservices (CDMO), Kronos Bio (KRON), Zymeworks (ZYME), COMPASS Pathways (CMPS) and Shattuck Labs (STTK).
View all of NBRV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NBRV stock can currently be purchased for approximately $1.47.

Nabriva Therapeutics has a market capitalization of $367.86 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($11.20) on an earnings per share basis.

Nabriva Therapeutics employs 162 workers across the globe.

The official website for Nabriva Therapeutics is www.nabriva.com.

Nabriva Therapeutics is headquartered at 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406.

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company can be reached via phone at (531) 649-2000 or via email at [email protected]